SUTRO BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
SUTRO BIOPHARMA, INC. (STRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $30.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-25.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2024-03-25
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-03-31 was $100.00K, a 94.74% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-12-31 was $500.00K, a 54.55% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-09-30 was $100.00K, a 108.33% increase year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $30.00K, a 70.00% decline from fiscal 2022.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $100.00K, a 96.43% decline from fiscal 2021.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $2.80M, a 133.33% increase from fiscal 2020.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $1.20M, a 500.00% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|---|---|
| 2023-12-31 | $30.00K 10-K · filed 2024-03-25 | |||||
| 2022-12-31 | $100.00K 10-K · filed 2024-03-25 | |||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $100.00K 10-Q · filed 2022-08-08 | $600.00K derived: sum of 3 quarters · filed 2024-03-25 | $700.00K derived: sum of 4 quarters · filed 2024-03-25 | ||
| 2022-03-31 | $100.00K 10-Q · filed 2022-05-09 | $600.00K derived: sum of 2 quarters · filed 2024-03-25 | $700.00K derived: sum of 3 quarters · filed 2024-03-25 | $1.00M derived: sum of 4 quarters · filed 2024-03-25 | ||
| 2021-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $600.00K derived: sum of 2 quarters · filed 2024-03-25 | $900.00K derived: sum of 3 quarters · filed 2024-03-25 | $2.80M 10-K · filed 2024-03-25 | ||
| 2021-09-30 | $100.00K 10-Q · filed 2021-11-10 | $400.00K derived: sum of 2 quarters · filed 2022-08-08 | $2.30M 10-Q · filed 2021-11-10 | $3.40M derived: sum of 4 quarters · filed 2023-03-30 | ||
| 2021-06-30 | $300.00K 10-Q · filed 2022-08-08 | $2.20M 10-Q · filed 2022-08-08 | $3.30M derived: sum of 3 quarters · filed 2023-03-30 | $3.35M derived: sum of 4 quarters · filed 2023-03-30 | ||
| 2021-03-31 | $1.90M 10-Q · filed 2022-05-09 | $3.00M derived: sum of 2 quarters · filed 2023-03-30 | $3.05M derived: sum of 3 quarters · filed 2023-03-30 | $3.05M derived: sum of 4 quarters · filed 2023-03-30 | ||
| 2020-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.15M derived: sum of 2 quarters · filed 2023-03-30 | $1.15M derived: sum of 3 quarters · filed 2023-03-30 | $1.20M 10-K · filed 2023-03-30 | ||
| 2020-09-30 | $48.00K 10-Q · filed 2021-11-10 | $53.00K derived: sum of 2 quarters · filed 2021-11-10 | $100.00K 10-Q · filed 2021-11-10 | $129.00K 10-Q · filed 2020-11-05 | $210.00K derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | $5.00K 10-Q · filed 2021-08-09 | $81.00K 10-Q · filed 2021-08-09 | $162.00K derived: sum of 3 quarters · filed 2022-02-28 | $225.00K derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | $76.00K 10-Q · filed 2021-05-07 | $157.00K derived: sum of 2 quarters · filed 2022-02-28 | $220.00K derived: sum of 3 quarters · filed 2022-02-28 | $229.00K derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2019-12-31 | $81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $144.00K derived: sum of 2 quarters · filed 2022-02-28 | $153.00K derived: sum of 3 quarters · filed 2022-02-28 | $200.00K 10-K · filed 2022-02-28 | ||
| 2019-09-30 | $63.00K 10-Q · filed 2020-11-05 | $72.00K derived: sum of 2 quarters · filed 2020-11-05 | $119.00K 10-Q · filed 2020-11-05 | $165.00K derived: sum of 4 quarters · filed 2021-03-18 | ||
| 2019-06-30 | $9.00K 10-Q · filed 2020-08-06 | $55.00K 10-Q · filed 2020-08-06 | $102.00K derived: sum of 3 quarters · filed 2021-03-18 | $120.00K derived: sum of 4 quarters · filed 2021-03-18 | ||
| 2019-03-31 | $46.00K 10-Q · filed 2020-05-11 | $46.12K 10-Q · filed 2019-05-15 | $93.00K derived: sum of 2 quarters · filed 2021-03-18 | $111.00K derived: sum of 3 quarters · filed 2021-03-18 | $186.00K derived: sum of 4 quarters · filed 2021-03-18 | |
| 2018-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $65.00K derived: sum of 2 quarters · filed 2021-03-18 | $140.00K derived: sum of 3 quarters · filed 2021-03-18 | $200.00K 10-K · filed 2021-03-18 | ||
| 2018-09-30 | $18.00K 10-Q · filed 2019-11-08 | $18.27K 10-Q · filed 2018-11-14 | $93.00K derived: sum of 2 quarters · filed 2019-11-08 | $153.00K 10-Q · filed 2019-11-08 | $153.41K 10-Q · filed 2018-11-14 | $201.89K derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $75.00K 10-Q · filed 2019-08-14 | $135.00K 10-Q · filed 2019-08-14 | $183.89K derived: sum of 3 quarters · filed 2020-03-16 | $192.32K derived: sum of 4 quarters · filed 2020-03-16 | ||
| 2018-03-31 | $60.00K 10-Q · filed 2019-05-15 | $108.89K derived: sum of 2 quarters · filed 2020-03-16 | $117.32K derived: sum of 3 quarters · filed 2020-03-16 | |||
| 2017-12-31 | $48.89K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $57.32K derived: sum of 2 quarters · filed 2020-03-16 | $100.00K 10-K · filed 2020-03-16 | |||
| 2017-09-30 | $8.43K 10-Q · filed 2018-11-14 | $51.11K 10-Q · filed 2018-11-14 | ||||
| 2016-12-31 | $300.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |